Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Gary R. Matzke, George R. Aronoff, Arthur J. Atkinson, William M. Bennett, Brian Decker, Kai Uwe Eckardt, Thomas Golper, Darren W. Grabe, Bertram Kasiske, Frieder Keller, Jan T. Kielstein, Ravindra Mehta, Bruce A. Mueller, Deborah A. Pasko, Franz Schaefer, Domenic A. Sica, Lesley A. Inker, Jason G. Umans, Patrick Murray

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patients kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed the major challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

Original languageEnglish
Pages (from-to)1122-1127
Number of pages6
JournalKidney International
Volume80
Issue number11
DOIs
StatePublished - Dec 2011

Fingerprint

Kidney Diseases
Kidney
Chronic Renal Insufficiency
Pharmaceutical Preparations
Renal Replacement Therapy
Pharmacokinetics
United States Food and Drug Administration
Glomerular Filtration Rate
Research Personnel
Pediatrics
Research
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease : Improving Global Outcomes (KDIGO). / Matzke, Gary R.; Aronoff, George R.; Atkinson, Arthur J.; Bennett, William M.; Decker, Brian; Eckardt, Kai Uwe; Golper, Thomas; Grabe, Darren W.; Kasiske, Bertram; Keller, Frieder; Kielstein, Jan T.; Mehta, Ravindra; Mueller, Bruce A.; Pasko, Deborah A.; Schaefer, Franz; Sica, Domenic A.; Inker, Lesley A.; Umans, Jason G.; Murray, Patrick.

In: Kidney International, Vol. 80, No. 11, 12.2011, p. 1122-1127.

Research output: Contribution to journalArticle

Matzke, GR, Aronoff, GR, Atkinson, AJ, Bennett, WM, Decker, B, Eckardt, KU, Golper, T, Grabe, DW, Kasiske, B, Keller, F, Kielstein, JT, Mehta, R, Mueller, BA, Pasko, DA, Schaefer, F, Sica, DA, Inker, LA, Umans, JG & Murray, P 2011, 'Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)', Kidney International, vol. 80, no. 11, pp. 1122-1127. https://doi.org/10.1038/ki.2011.322
Matzke, Gary R. ; Aronoff, George R. ; Atkinson, Arthur J. ; Bennett, William M. ; Decker, Brian ; Eckardt, Kai Uwe ; Golper, Thomas ; Grabe, Darren W. ; Kasiske, Bertram ; Keller, Frieder ; Kielstein, Jan T. ; Mehta, Ravindra ; Mueller, Bruce A. ; Pasko, Deborah A. ; Schaefer, Franz ; Sica, Domenic A. ; Inker, Lesley A. ; Umans, Jason G. ; Murray, Patrick. / Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease : Improving Global Outcomes (KDIGO). In: Kidney International. 2011 ; Vol. 80, No. 11. pp. 1122-1127.
@article{a40b18f94ed047bc8321e65661194708,
title = "Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)",
abstract = "Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patients kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed the major challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.",
author = "Matzke, {Gary R.} and Aronoff, {George R.} and Atkinson, {Arthur J.} and Bennett, {William M.} and Brian Decker and Eckardt, {Kai Uwe} and Thomas Golper and Grabe, {Darren W.} and Bertram Kasiske and Frieder Keller and Kielstein, {Jan T.} and Ravindra Mehta and Mueller, {Bruce A.} and Pasko, {Deborah A.} and Franz Schaefer and Sica, {Domenic A.} and Inker, {Lesley A.} and Umans, {Jason G.} and Patrick Murray",
year = "2011",
month = "12",
doi = "10.1038/ki.2011.322",
language = "English",
volume = "80",
pages = "1122--1127",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease

T2 - Improving Global Outcomes (KDIGO)

AU - Matzke, Gary R.

AU - Aronoff, George R.

AU - Atkinson, Arthur J.

AU - Bennett, William M.

AU - Decker, Brian

AU - Eckardt, Kai Uwe

AU - Golper, Thomas

AU - Grabe, Darren W.

AU - Kasiske, Bertram

AU - Keller, Frieder

AU - Kielstein, Jan T.

AU - Mehta, Ravindra

AU - Mueller, Bruce A.

AU - Pasko, Deborah A.

AU - Schaefer, Franz

AU - Sica, Domenic A.

AU - Inker, Lesley A.

AU - Umans, Jason G.

AU - Murray, Patrick

PY - 2011/12

Y1 - 2011/12

N2 - Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patients kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed the major challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

AB - Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patients kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed the major challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=81155133673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155133673&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.322

DO - 10.1038/ki.2011.322

M3 - Article

C2 - 21918498

AN - SCOPUS:81155133673

VL - 80

SP - 1122

EP - 1127

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 11

ER -